Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status.
about
The urgent need to recover MHC class I in cancers for effective immunotherapyTargeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer ImmunityThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyEpigenetics in Cancer: A Hematological PerspectiveThe impact of the Cancer Genome Atlas on lung cancer.Augmenting antitumor immune responses with epigenetic modifying agents.Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype.Improving cancer immunotherapy with DNA methyltransferase inhibitors.Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines.DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes.Improving radiotherapy in cancer treatment: Promises and challenges.Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes.The Role of Tumor Microenvironment in Cancer Immunotherapy.
P2860
Q26770165-73FA01EC-0C2C-463E-8005-49B02704F246Q26797280-972BF676-6F81-4FF8-B59C-FFAE2DBC0AD5Q28076473-FA00547C-315E-412D-8BE7-040E5BE5F79EQ28077082-F27AA9A6-53A9-40FB-BD03-B2E31D4061FCQ28084190-8A1A9278-8ADA-481D-9006-F0A390FA189CQ35048054-6382BEC5-0182-49F2-81BE-10A503DF4049Q37420192-357FC6C6-0CEF-49BE-9437-38D111939171Q38282541-1525647C-57A5-48C3-A785-A6C748AC9536Q38662760-20DB2047-CC7B-40F5-9B82-F90BF851199EQ38838643-CE005FF1-606C-47AB-8722-361B9E3ED80BQ38988078-6AD11CDA-E7E3-46FD-855B-14B27E8E6E61Q39569192-0BC1482E-BF3E-4CF6-975A-9C9AF4778AE1Q41247038-E2628789-54BA-466E-BD38-4F8BCE8ABD19Q41887350-AEAD5EE0-A653-4A3E-92FF-65318452C1C9Q41899048-4BF1F68D-5ED4-4B5D-A9BA-B0CC03460F3BQ42152245-C740C86E-7CBC-4A95-ADE9-81478DAC8BA7Q47252754-BA3791B9-DB97-430C-B709-63167E57F7B9
P2860
Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Immunotherapy augments the eff ...... MHC class I-expression status.
@en
Immunotherapy augments the eff ...... MHC class I-expression status.
@nl
type
label
Immunotherapy augments the eff ...... MHC class I-expression status.
@en
Immunotherapy augments the eff ...... MHC class I-expression status.
@nl
prefLabel
Immunotherapy augments the eff ...... MHC class I-expression status.
@en
Immunotherapy augments the eff ...... MHC class I-expression status.
@nl
P2093
P2860
P356
P1476
Immunotherapy augments the eff ...... MHC class I-expression status.
@en
P2093
I Stěpánek
J Bieblová
R Mikyšková
V Polláková
P2860
P2888
P304
P356
10.1038/BJC.2011.428
P407
P577
2011-10-20T00:00:00Z